Clinical Trial Goal
To find out if epcoritamab, before CAR T-cell therapy, is safe and works well to treat large B-cell lymphoma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have large B-cell lymphoma that has relapsed or is refractory. Some examples include:
- Diffuse large B-cell lymphoma (DLBCL)
- Primary mediastinal large B-cell lymphoma (PMBCL)
- Have cancer cells with marker CD20 (CD20+). Your doctor can tell you this
- Are able to receive commercially available CAR T-cell therapy. Your doctor can tell you this
- Do not have lymphoma in your brain or spinal cord
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Epcoritamab is a bispecific monoclonal antibody that targets CD3 and CD20 on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Epcoritamab – Given as a shot under your skin 1 time each day
You may continue treatment for 3 months. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has approved epcoritamab to treat DLBCL and follicular lymphoma. Using in in this way before CAR T-cell therapy is new and unproven.
Contacts
Brittany Koch, 215-776-5548, Brittany.Koch@pennmedicine.upenn.edu
Kaitlin Kennard, Kaitlin.Kennard@pennmedicine.upenn.edu
Locations
Abramson Cancer Center at the University of PennsylvaniaRECRUITING
Philadelphia, Pennsylvania
Contacts:
- Brittany Koch, 215-776-5548, Brittany.Koch@pennmedicine.upenn.edu
- Kaitlin Kennard, Kaitlin.Kennard@pennmedicine.upenn.edu
Sponsors
collaborator: Genmab, lead: Abramson Cancer Center at Penn Medicine
